• Explore /
  • Poster
  • / A phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti–PD-1) in patients with metastatic castration-resistant prostate cancer.

A phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti–PD-1) in patients with metastatic castration-resistant prostate cancer.

Abstract Poster

Authors

null

Jingsong Zhang

Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL

Jingsong Zhang , Mark N. Stein , William Kevin Kelly , Che-Kai Tsao , Gerald Steven Falchook , Yuanfang Xu , Frank A. Seebach , Israel Lowy , Kosalai Kal Mohan , Glenn Kroog , Elizabeth Miller

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session: Advanced Prostate Cancer

Track

Prostate Cancer - Advanced

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03972657

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr TPS174)

DOI

10.1200/JCO.2021.39.6_suppl.TPS174

Abstract #

TPS174

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Charles G. Drake

First Author: William Kevin Kelly

First Author: Mark N. Stein

First Author: Niven Mehra